Meditab Holdings Ltd (MHL), a wholly owned step down subsidiary of the company, has acquired an additional 14.5 per cent stake in QCIL, Cipla Ltd said in a filing to the BSE.
"MHL was earlier holding 36.55 per cent stake in QCIL. Consequent to the acquisition of aforesaid additional stake, MHL now holds 51.05 per cent stake in QCIL," it added.
QCIL's principal activity is manufacturing and selling of pharmaceutical drugs with emphasis on anti-retroviral (ARVs) and anti-malarial drugs. QCIL has a WHO approved manufacturing facility in Uganda, the filing added.
Cipla is among the big generic drug makers in the world and is one of the largest exporters of pharma products from India, shipping API and formulation products to over 170 countries such as US and Canada as well as those in Europe, Africa, Australasia, Latin America and the Middle East.
Shares of Cipla ltd were trading at Rs 389.65 per scrip in the afternoon trade, down 0.81 per cent from the previous close on the BSE.